Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients with prior failure to DAA treatment

被引：0
|
作者：
Graf, Christiana [1 ]
Degasperi, Elisabetta [2 ]
D'Ambrosio, Roberta [2 ]
Llaneras, Jordi [3 ]
Vermehren, Johannes [1 ]
Dultz, Georg [1 ]
Wetzstein, Nils [4 ]
Herrmann, Eva [5 ]
Zeuzem, Stefan [1 ]
Buti, Maria
Lampertico, Pietro
Dietz, Julia [1 ]
Sarrazin, Christoph [1 ,6 ]
机构：
[1] Univ Hosp Frankfurt, Dept Internal Med, Frankfurt, Germany
[2] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy
[3] UAB Univ Autonoma Barcelona, Hosp Univ Vall Hebron, Dept Med, Barcelona, Spain
[4] Univ Hosp Frankfurt, Dept Internal Med Infect Dis, Frankfurt, Germany
[5] Goethe Univ Frankfurt, Inst Biostatist & Math Modeling, Frankfurt, Germany
[6] St Josefs Hosp, Med Klin II, Wiesbaden, Germany
来源：
JOURNAL OF HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OS-129-YI
引用
收藏
页码：S98 / S99
页数：2
相关论文
共 50 条
  • [21] Clinical and virological characteristics of patients with chronic hepatitis C and failure to voxilaprevir/velpatasvir/sofosbuvir treatment
    Dietz, Julia
    de Salazar, Adolfo
    Vermehren, Johannes
    Merino, Dolores
    zur Wiesch, Julian Schulze
    Lara, Magdalena
    Rodriguez Pardo, Maria Josefa
    Di Maio, Velia Chiara
    Paolucci, Stefania
    Degasperi, Elisabetta
    Zoller, Heinz
    Arenas Ruiz-Tapiador, Juan Ignacio
    Stauber, Rudolf E.
    Figueruela, Blanca
    Buti, Maria
    Lampertico, Pietro
    Zeuzem, Stefan
    Silberstein, Francesca Ceccherini
    Garcia Garcia, Federico
    Sarrazin, Christoph
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E219 - E220
  • [22] EARLY PLASMA AND INTRAHEPATIC HEPATITIS C VIRUS KINETICS DURING DAA TREATMENT WITH SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR
    Balagopal, Ashwin
    Sachithanandham, Jaiprasath
    Quinn, Jeffrey
    Leep-Lazar, Julia
    Bowden, Kenneth
    Ward, Kathleen
    Sulkowski, Mark S.
    HEPATOLOGY, 2019, 70 : 981A - 982A
  • [23] Sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection
    Kilaru, Saikiran M.
    Jacobson, Ira M.
    FUTURE VIROLOGY, 2019, 14 (02) : 61 - 71
  • [24] Final challenges: real-world experience with sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis
    Papaluca, Tim
    Roberts, Stuart
    Strasser, Simone
    Stuart, Katherine
    New, Kate
    Farrell, Geoff
    Dore, Gregory
    Wigg, Alan
    Woodward, Aidan
    Wade, Amanda
    George, Jacob
    Sinclair, Marie
    McGarity, Bruce
    Fisher, A. Leslie
    Sawhney, Rohit
    Wilson, Mark
    Valiozis, Ivan
    Levy, Miriam
    Tse, Edmund
    Ahlenstiel, Golo
    Haque, Mazhar
    Prewett, Emily
    Sievert, William
    Sood, Siddharth
    O'Beirne, James
    Thomas, James
    Hazeldine, Simon
    Valaydon, Zina
    Douglas, Mark
    Bowden, Scott
    O'Keefe, Jacinta
    Holmes, Jacinta
    Thompson, Alexander
    JOURNAL OF HEPATOLOGY, 2020, 73 : S363 - S363
  • [25] Retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and prior DAA failure: An analysis from the German hepatitis C registry (DHC-R)
    Vermehren, Johannes
    Stoehr, Albrecht
    Wiesch, Julian Schulze Zur
    Klinker, Hartwig
    Cornberg, Markus
    Maria-Christina, Jung
    Simon, Karl-Georg
    Serfert, Yvonne
    Manns, Michael P.
    Wedemeyer, Heiner
    Sarrazin, Christoph
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E245 - E245
  • [26] Real-world retreatment of HCV-infected patients with prior failure to direct acting antiviral therapy using sofosbuvir, velpatasvir and voxilaprevir
    Smith, David A.
    Bradshaw, Daniel
    Mbisa, Jean
    Manso, Carmen
    Bibby, David
    Singer, Josh
    Thomson, Emma
    Filipe, Anna da Silva
    Aranday-Cortes, Elihu
    Ansari, Azim
    Brown, Anthony
    Hudson, Emma
    Benselin, Jennifer
    Healy, Brendan
    Troke, Phil
    Mclauchlan, John
    Barnes, Eleanor
    Irving, William
    JOURNAL OF HEPATOLOGY, 2020, 73 : S336 - S336
  • [27] EFFECTIVENESS OF SOFOSBUVIR / VELPATASVIR IN TREATING HEPATITIS C VIRUS INFECTION IN A REAL-WORLD SETTING
    Wilton, James
    Wong, Stanley
    Yu, Amanda
    Cook, Darrel
    Butt, Zahid Ahmad
    Alvarez, Maria Jose
    Binka, Mawuena
    Darvishian, Maryam
    Yoshida, Eric M.
    Ramji, Alnoor
    Krajden, Mel
    Janjua, Naveed
    HEPATOLOGY, 2019, 70 : 983A - 983A
  • [28] Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3
    Belperio, Pamela S.
    Shahoumian, Troy A.
    Loomis, Timothy P.
    Mole, Larry A.
    Backus, Lisa I.
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : 15 - 23
  • [29] Sofosbuvir/Velpatasvir/Voxilaprevir Experience in Treatment-Naive Chronic Hepatitis C Patients: Preliminary Findings of Real World Data
    Cakirca, Tuba Damar
    Yamazhan, Tansu
    Yuksekkaya, Esra
    Akgul, Fethiye
    Kurtaran, Behice
    Karasahin, Omer
    Karabay, Oguz
    Unlu, Gulten
    Can, Ilkay Nur
    Pullukcu, Husnu
    Tasova, Yesim
    Komur, Suheyla
    Yildiz, Yesim
    Mermutluoglu, Cigdem
    Demir, Yakup
    Celen, Mustafa Kemal
    VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, 2023, 29 (02): : 58 - 63
  • [30] Retreatment with Voxilaprevir/Velpatasvir/Sofosbuvir in Patients with Chronic Hepatitis C Virus Infection and Prior Daa Failure - Results from the German Hepatitis C-Registry (DHC-R)
    Vermehren, Johannes
    Stoehr, Albrecht
    Zur Wiesch, Julian Schulze
    Klinker, Hartwig
    Cornberg, Markus
    Jung, Maria-Christina
    Simon, Karl-Georg
    Serfert, Yvonne
    Manns, Michael P.
    Wedemeyer, Heiner
    Sarrazin, Christoph
    HEPATOLOGY, 2018, 68 : 401A - 402A
12345